Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

A Phase II Study of Gemcitabine at Fixed Infusion Rate of 10 mg/m2/min with or without Immunotherapy in Advanced Renal Cancer

FABLE ZUSTOVICH, GIUSEPPE CARTEI, DAVIDE PASTORELLI, ORNELLA NICOLETTO, FEDRA GOTTARDO, LUCA DE ZORZI and MASSIMO DAL BIANCO
Anticancer Research November 2007, 27 (6C) 4461-4464;
FABLE ZUSTOVICH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: fable.zustovich@ioveneto.it
GIUSEPPE CARTEI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAVIDE PASTORELLI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ORNELLA NICOLETTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FEDRA GOTTARDO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LUCA DE ZORZI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASSIMO DAL BIANCO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Advanced renal cancer remains a challenge for oncologists since no treatment other than surgery has demonstrated a clear survival advantage. Patients and Methods: Gemcitabine was given to suitable patients at a fixed infusion rate of 10 mg/m2/min. Eighteen patients received concomitant immunotherapy, mostly low doses of interleukin 2 (IL2). Results: Thirty patients were enrolled. The overall response rate was 14% (22% in the subset of patients treated with both chemotherapy and immunotherapy) with a median progression-free survival time of 4.1+ months. Toxicity was not mild, mostly fatigue, nausea and anaemia, even though not life threatening. Conclusion: Gemcitabine at the fixed infusion rate of 10 mg/m2/min with concomitant low doses of IL2 could be useful in the palliative treatment of symptomatic patients with renal carcinoma progressing after tyrosine kinases inhibitor.

  • Kidney cancer
  • gemcitabine
  • immunotherapy

Footnotes

  • Received July 25, 2007.
  • Revision received October 12, 2007.
  • Accepted October 22, 2007.
  • Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 27 (6C)
Anticancer Research
Vol. 27, Issue 6C
November-December 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Phase II Study of Gemcitabine at Fixed Infusion Rate of 10 mg/m2/min with or without Immunotherapy in Advanced Renal Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
A Phase II Study of Gemcitabine at Fixed Infusion Rate of 10 mg/m2/min with or without Immunotherapy in Advanced Renal Cancer
FABLE ZUSTOVICH, GIUSEPPE CARTEI, DAVIDE PASTORELLI, ORNELLA NICOLETTO, FEDRA GOTTARDO, LUCA DE ZORZI, MASSIMO DAL BIANCO
Anticancer Research Nov 2007, 27 (6C) 4461-4464;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
A Phase II Study of Gemcitabine at Fixed Infusion Rate of 10 mg/m2/min with or without Immunotherapy in Advanced Renal Cancer
FABLE ZUSTOVICH, GIUSEPPE CARTEI, DAVIDE PASTORELLI, ORNELLA NICOLETTO, FEDRA GOTTARDO, LUCA DE ZORZI, MASSIMO DAL BIANCO
Anticancer Research Nov 2007, 27 (6C) 4461-4464;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Gemcitabine for the Treatment of Classic Kaposi's Sarcoma: A Case Series
  • Google Scholar

More in this TOC Section

  • Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
  • End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report
  • Effect of a Biweekly Dosing Schedule on Severe Neutropenia Induced by Trifluridine/Tipiracil in Colorectal Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire